PATENT CLAIM ANALYSIS

Application Number: 16033953
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "377000"]

Abstract:
The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Claim (Index 6):
The method according to claim, wherein the MEK inhibitor is trametinib, selumetinib, RO5068760, MEK162, PD-325901, cobimetinib, CI-1040 or any combination thereof.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 95.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13676650', '13216927', '12981233', '14049950', '14692597']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8253013453170082
- 35 USC 102 Novelty (BERT): 0.5553927871649033
- Combined Prediction Score: 0.7983104895017977
- Mean Citation Score: 433.06619600000016
- Max Citation Score: 478.3542
- Similarity Product: 288.3412823002696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test